Clinics in Dermatology
Volume 26, Issue 3 , Pages 255-264 , May 2008

Cutaneous manifestations of chronic kidney disease

References 

  1. Bencini PL, Montagnino G, Citterio A, Graziani G, Crosti C, Ponticelli C. Cutaneous abnormalities in uremic patients. Nephron. 1985;40:316–321
  2. Stahle-Backdahl M. Uremic pruritus: clinical and experimental studies. Acta Derm Venereol (Stockh). 1989;145:1–38
  3. Gilchrest BA, Stern RS, et al. Clinical features of pruritus among patients undergoing maintenance hemodialysis. Arch Dermatol. 1982;118:154–157
  4. Hampers CL, Katz AI, et al. Disappearance of uremic itching after subtotal parathyroidectomy. N Engl J Med. 1968;279:695–697
  5. Chou FF. A study on pruritus after parathyroidectomy for secondary hyperparathyroidism. J Am Coll Surg. 2000;190:65–70
  6. Stahle-Backdahl M. Uremic pruritus. Semin Dermatol. 1995;14:297–301
  7. Kato A. Pruritus and hydration state of stratum corneum in hemodialysis patients. Am J Nephrol. 2000;20:437–442
  8. Vanholder R, Smet RD. Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol. 1999;10:1815–1823
  9. Zakrzewska-Pniewska B, Jedras M. Is pruritus in chronic uremic patients related to peripheral somatic and autonomic neuropathy?. Neurophysiol Clin. 2001;31:181–193
  10. Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritus—new perspectives and insights from recent trials. Nephrol Dial Transplant. 2002;17:1558–1563
  11. Garssen J, Vandebriel RJ, et al. UVB exposure–induced systemic modulation of Th1- and Th2-mediated immune responses. Immunology. 1999;97:506–514
  12. Andersen LW, Friedberg M, Lokkegaard N. Naloxone in treatment of uremic pruritus: a case history. Clin Nephrol. 1984;21:355–356
  13. Peer G, Kivity S, et al. Randomized crossover trial of naltrexone in uraemic pruritus. Lancet. 1996;348:1552–1554
  14. Breneman DL, Cardone JS, et al. Topical capsaicin for the treatment of hemodialysis-related pruritus. J Am Acad Dermatol. 1992;26:91–94
  15. Pauli-Magnus C, Klumpp S, et al. Short-term efficacy of tacrolimus ointment in severe uremic pruritus. Perit Dial Int. 2000;6:802–803
  16. Peck LW, Monsen ER, Ahmed S. Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentration and pruritus symptoms in hemodialysis patients. Am J Clin Nutr. 1996;64:210–214
  17. Yoshimoto-Furuie K, Yoshimoto K, et al. Effects of oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids and uremic skin symptoms in hemodialysis patients. Nephron. 1999;81:151–159
  18. Hiroshige K, Kabashima N, et al. Optimal dialysis improves uremic pruritus. Am J Kidney Dis. 1995;25:413–419
  19. Gilchrest BA, Rowe JW, et al. Ultraviolet phototherapy of uremic pruritus: long-term results and possible mechanisms of action. Ann Intern Med. 1979;91:17–21
  20. Fjellner B. Experimental and clinical pruritus. Acta Derm Venereol (Stockh). 1981;97:1–34
  21. Shapiro R, Stockard H. Successful treatment of uremic pruritus: the acupuncture approach revisited. Dial Transplant. 2003;32:257–265
  22. Taipa L, Cheigh JS, David DS. Pruritus in dialysis patients treated with parenteral lidocaine. N Engl J Med. 1977;296:261
  23. Schwartz IF, Iaina A. Uraemic pruritus. Nephrol Dial Transplant. 1999;14:834–839
  24. Silverberg DS, Iaina A, et al. Cholestyramine in uremic pruritus. BMJ. 1977;1:752–753
  25. Yatzidis H, Digenis P, Tountas C. Heparin treatment in uremic itching. JAMA. 1972;222:1183–1184
  26. De Marchi S, Cecchin E, et al. Relief of pruritus and decreases in plasma histamine concentration during erythropoietin therapy in patients with uremia. N Engl J Med. 1992;326:969–974
  27. Balaskas EV, Bamihas GI, et al. Histamine and serotonin in uremic pruritus: effect of ondansetron in CAPD-pruritic patients. Nephron. 1998;78:395–402
  28. Bousquet J, Rivory JP, et al. Double-blind, placebo-controlled study of nicergoline in the treatment of pruritus in patients receiving maintenance hemodialysis. J Allergy Clin Immunol. 1989;83:825–828
  29. Gunal AI, Ozalp G, et al. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant. 2004;19:3137–3139
  30. Rosner MH. Cromolyn sodium: a potential therapy for uremic pruritus?. Hemodial Int. 2006;10:189–192
  31. Farrell AM. Acquired perforating dermatosis in renal and diabetic patients. Lancet. 1997;349
  32. Pedragosa R, Knobel HJ, et al. Reactive perforating collagenosis in Hodgkin's disease. Am J Dermatopathol. 1987;9:41–44
  33. Morton CA, Henderson IS, et al. Acquired perforating dermatosis in a British dialysis population. Br J Dermatol. 1996;135:671–677
  34. Hood A, Hardegen GL, et al. Kyrle's disease in patients with chronic renal failure. Arch Dermatol. 1982;118:85–88
  35. Patterson JW, Brown PC. Ultrastructural changes in acquired perforating dermatosis. Int J Dermatol. 1992;31:201–205
  36. Zelger B, Hintner H, et al. Acquired perforating dermatosis: transepidermal elimination of DNA material and possible role of leukocytes in pathogenesis. Arch Dermatol. 1991;127:695–700
  37. Haftek M, Euvrard S, et al. Acquired perforating dermatosis of diabetes mellitus and renal failure: further ultrastructural clues to its pathogenesis. J Cutan Pathol. 1993;330–335
  38. Blanchley JD, Blankenship M, et al. Uraemic pruritus: skin divalent ion content and response to ultraviolet therapy. Am J Kidney Dis. 1985;5:237–241
  39. Morgan MB, Truitt CA, et al. Fibronectin and the extracellular matrix in the perforating disorders of the skin. Am J Dermatopathol. 1998;20:147–154
  40. Saldanha LF, Gonick HC, et al. Silicon-related syndrome in dialysis patients. Nephron. 1997;77:48–56
  41. Hudson JB, Dennis AJ. Transverse white lines in the fingernails after acute and chronic renal failure. Arch Intern Med. 1966;117:276–279
  42. Seavolt MB, Sarro RA, Levin K, Camisa C. Mees' lines in a patient following acute arsenic intoxication. Int J Dermatol. 2002;41:399–401
  43. Leyden JJ, Wood MG. The “half-and-half nail”: a uremic onychopathy. Arch Dermatol. 1972;105:591–592
  44. Tercedor J, Lopez Hernandez B, Manuel Rodenas J. Nail diseases in haemodialysis patients: case-control study. Br J Dermatol. 2001;144:445–446
  45. Lindsay PG. The half-and-half nail. Arch Intern Med. 1967;119:583–587
  46. Lubach D, Strubbe J, Schmidt J. The ‘half and half nail’ phenomenon in chronic hemodialysis patients. Dermatologica. 1982;164:350–353
  47. Stewart WK, Raffle EJ. Brown nail-bed arcs and chronic renal disease. Br Med J. 1972;1:784–786
  48. Saray Y, Seckin D, Gulec AT, Akgun S, Haberal M. Nail disorders in hemodialysis patients and renal transplant recipients: a case-control study. J Am Acad Dermatol. 2004;50:197–202
  49. Poh-Fitzpatrick MB, Masullo AS, Grossman ME. Porphyria cutanea tarda associated with chronic renal disease and hemodialysis. Arch Dermatol. 1980;116:191–195
  50. Glynne P, Deacon A, Goldsmith D, Pusey C, Clutterbuck E. Bullous dermatoses in end-stage renal failure: porphyria or pseudoporphyria?. Am J Kidney Dis. 1999;34:155–160
  51. Mamet R, Gafter U, Korzets A, Schoenfeld N. Decreased uroporphyrinogen decarboxylase activity in patients with end-stage renal disease undergoing hemodialysis. Nephron. 1995;70:202–206
  52. Albalate M, Farinas MC, Octavio JG, Perez JH, Goicoechea M, Caramelo C. Development of porphyria cutanea tarda in a hemodialysis patient after reactivation of hepatitis C virus infection. Nephron. 2001;88:170–173
  53. Topi GC, Alessandro GL, Cancarini GC, De Costanza F, Griso D, Ravelli M. Porphyria cutanea tarda in a haemodialysed patient. Br J Dermatol. 1981;104:579–580
  54. Keczkes K, Farr M. Bullous dermatosis of chronic renal failure. Br J Dermatol. 1976;95:541–546
  55. Harber LC, Bickers DR. Porphyria and pseudoporphyria. J Invest Dermatol. 1984;82:207–209
  56. Stevens BR, Fleischer AB, Piering F, Crosby DL. Porphyria cutanea tarda in the setting of renal failure. Response to renal transplantation. Arch Dermatol. 1993;129:337–339
  57. Vadoud-Seyedi J, de Dobbeleer G, Simonart T. Treatment of haemodialysis-associated pseudoporphyria with N-acetylcysteine: report of two cases. Br J Dermatol. 2000;142:580–581
  58. Khan IU, Bhol KC, Ahmed AR. Linear IgA bullous dermatosis in a patient with chronic renal failure: response to intravenous immunoglobulin therapy. J Am Acad Dermatol. 1999;40:485–488
  59. Serwin AB, Mysliwiec H, Laudanska H, Chodynicka B. Linear IgA bullous dermatosis in a diabetic patient with chronic renal failure. Int J Dermatol. 2002;41:778–780
  60. Mazhar AR, Johnson RJ, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 2001;60:324–332
  61. Shearer MJ. Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification. Curr Opin Clin Nutr Metab Care. 2000;3:433–438
  62. Zacharias JM, Fontaine B, Fine A. Calcium use increases risk of calciphylaxis: a case-control study. Perit Dial Int. 1999;19:248–252
  63. Mori K, Shioi A, et al. Dexamethasone enhances in vitro vascular calcification by promoting osteoblastic differentiation of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19:2112–2118
  64. Coates T, Kirkland GS, et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis. 1998;32:384–391
  65. Janigan DT, Hirsch DJ, et al. Calcified subcutaneous arterioles with infarcts of the subcutis and skin (“calciphylaxis”) in chronic renal failure. Am J Kidney Dis. 2000;35:588–597
  66. Llach F. The evolving pattern of calciphylaxis: therapeutic considerations. Nephrol Dial Transplant. 2001;16:448–451
  67. Dwyer KM, Francis DMA, et al. Calcific uraemic arteriolopathy: local treatment and hyperbaric oxygen therapy. Nephrol Dial Transplant. 2002;17:1148–1149
  68. Auron A, Shao L, Warady BA. Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol. 2006;[electronic publication ahead of print]
  69. Streams BN, Vincent V, Liégeois N, Moschella SM. Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. J Am Acad Dermatol. 2003;48:42–47
  70. Gilliet M, Cozzio A, Burg G, Nestle FO. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol. 2005;152:531–536
  71. Ruiz-Genao DP, Pascual-Lopez MP, Fraga S, Aragues M, Garcia-Diez A. Osseous metaplasia in the setting of nephrogenic fibrosing dermopathy. J Cutan Pathol. 2005;32:172–175
  72. Glaich AS, Martinelli PT, Markus RF, Hsu S. Generalized elastolysis following nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2005;53:174–176
  73. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003;139:903–906
  74. Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD. Nephrogenic fibrosing dermopathy. A novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003;114:563–572
  75. Mackay-Wiggan JM, Cohen DJ, Hardy MA, Knobler EH, Grossman ME. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol. 2003;48:55–60
  76. Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant. 2006;21:1104–1108
  77. Moreno-Romero JA, Segura S, Mascaro JM Jr, Cowper SE, Julia M, Poch E, et al. Nephrogenic systemic fibrosis. A case series suggesting gadolinium as a aetiological factor. Br J Dermatol. 2007;157:783–787
  78. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001;23:383–393
  79. Kucher C, Xu X, Pasha T, Elenitsas R. Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol. 2005;32:484–490
  80. Schmook T, Budde K, Ulrich C, Neumayer HH, Fritsche L, Stockfleth E. Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transplant. 2005;20:220–222
  81. Chung HJ, Chung KY. Nephrogenic fibrosing dermopathy. response to high-dose intravenous immunoglobulin. Br J Dermatol. 2004;150:596–597
  82. Kafi R, Fisher GJ, Quan T, et al. UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol. 2004;140:1322–1324

PII: S0738-081X(07)00240-4

doi: 10.1016/j.clindermatol.2007.10.017

Clinics in Dermatology
Volume 26, Issue 3 , Pages 255-264 , May 2008

Article Tools

* Image Usage & Resolution